| Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization LM McCormick, SP Hoole, PA White, PA Read, RG Axell, SJ Clarke, ... JACC: Cardiovascular Interventions 8 (2), 292-301, 2015 | 54 | 2015 |
| Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1 SJ Clarke, LM McCormick, DP Dutka Cardiovascular Diabetology 13, 1-10, 2014 | 41 | 2014 |
| Glucagon-like peptide-1: a promising agent for cardioprotection during myocardial ischemia JP Giblett, SJ Clarke, DP Dutka, SP Hoole JACC: Basic to Translational Science 1 (4), 267-276, 2016 | 35 | 2016 |
| Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus LM McCormick, PM Heck, LS Ring, AC Kydd, SJ Clarke, SP Hoole, ... Cardiovascular diabetology 14, 1-13, 2015 | 26 | 2015 |
| The impact of rarity in NICE’s health technology appraisals S Clarke, M Ellis, J Brownrigg Orphanet Journal of Rare Diseases 16 (1), 218, 2021 | 21 | 2021 |
| Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies JP Giblett, RG Axell, PA White, SJ Clarke, L McCormick, PA Read, ... Cardiovascular diabetology 15, 1-12, 2016 | 18 | 2016 |
| GLP‐1 is a coronary artery vasodilator in humans SJ Clarke, JP Giblett, LL Yang, A Hubsch, T Zhao, ... Journal of the American Heart Association 7 (22), e010321, 2018 | 16 | 2018 |
| Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion JP Giblett, RG Axell, PA White, M Aetesam-Ur-Rahman, SJ Clarke, N Figg, ... JACC: Basic to Translational Science 4 (2), 222-233, 2019 | 6 | 2019 |
| Association between virtual histology intravascular ultrasound findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable … PA Calvert, D Obaid, N West, L Shapiro, D McNab, C Densem, ... J. Am. Coll. Cardiol. Imaging 4, 894-901, 2011 | 5 | 2011 |
| The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial JP Giblett, S Clarke, T Zhao, LM McCormick, DM Braganza, CG Densem, ... American Heart Journal 215, 41-51, 2019 | 4 | 2019 |
| GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated M Aetesam-ur-Rahman, JP Giblett, B Khialani, S Kyranis, SJ Clarke, ... BMC Cardiovascular Disorders 21 (1), 223, 2021 | 3 | 2021 |
| Effects of acute GLP-1 infusion on pulmonary and systemic hemodynamics in patients with heart failure: a pilot study SJ Clarke, S Pettit, JP Giblett, T Zhao, AC Kydd, NJW Albrechtsen, ... Clinical Therapeutics 41 (1), 118-127. e0, 2019 | 3 | 2019 |
| Pre-treatment with glucagon-like peptide-1 protects against supply ischemic left ventricular dysfunction-insights from conductance catheter assessment during elective PCI LM McCormick, SP Hoole, PA White, PA Read, R Axell, SJ Clarke, ... Circulation 128 (suppl_22), A17497-A17497, 2013 | 2 | 2013 |
| Glucagon-like peptide-1 improves the myocardial response to demand ischemia during hyperglycemia in patients with type 2 diabetes mellitus and coronary artery disease LM McCormick, AC Kydd, LS Ring, SJ Clarke, DP Dutka Circulation 128 (suppl_22), A17348-A17348, 2013 | 2 | 2013 |
| Whole cycle non-hyperaemic pressure ratios have better stability than diastolic ratios after percutaneous coronary intervention due to changes in diastolic coronary haemodynamics M Aetesam-Ur-Rahman, T Zhao, K Paques, J Oliveira, B Khialani, ... European Heart Journal 42 (Supplement_1), ehab724. 2093, 2021 | | 2021 |
| The Cardiovascular Effect of GLP-1 in Humans S Clarke | | 2019 |
| TCT-597 GLP-1 does not protect against right ventricular stunning or cumulative ischemic dysfunction following right coronary artery balloon occlusion in humans. J Giblett, R Axell, M Aetesam-ur-Rahman, S Clarke, D Braganza, N West, ... Journal of the American College of Cardiology 72 (13S), B239-B239, 2018 | | 2018 |
| TCT-599 The GlucagOn-like peptide 1 Loading During PCI (GOLD PCI) trial: 12-month clinical outcomes J Giblett, S Clarke, L McCormick, T Zhao, S Villar, S Fielding, D Braganza, ... Journal of the American College of Cardiology 72 (13S), B240-B240, 2018 | | 2018 |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) HAS NO EFFECT ON PERIPHERAL VASODILATATION BUT AUGMENTS CORONARY MICROCIRCULATORY FLOW IN HUMANS SP Hoole, S Clarke, J Giblett, M Aetesam-ur-Rahman, T Zhao, N West, ... Journal of the American College of Cardiology 71 (11S), A20-A20, 2018 | | 2018 |
| 8 Glugacon-like petide 1 loading during percutaneous coronary intervention (GOLD PCI) trial JP Giblett, SJ Clarke, LM McCormick, D Braganza, CG Densem, ... Heart 104 (Suppl 1), A5-A5, 2018 | | 2018 |
Dr Liam M McCormickUniversity of CambridgeVerifierad e-postadress på doctors.org.uk
